Off-label uses of bevacizumab: breast and lung cancer indications.
D020533:Angiogenesis Inhibitors / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000556:secondary; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000556:secondary; D017277:Drug Approval; D004348:Drug Labeling; D006801:Humans; D007155:Immunologic Factors; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D009362:Neoplasm Metastasis; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D042461:Vascular Endothelial Growth Factor A